Long-Acting Strategies for Antibody Drugs: Structural Modification, Controlling Release, and Changing the Administration Route [0.03%]
长效抗体药物策略：结构改造、控制释放和改变给药方式
Hao Wang,Mengdi Song,Jiaqi Xu et al.
Hao Wang et al.
Because of their high specificity, high affinity, and targeting, antibody drugs have been widely used in the treatment of many diseases and have become the most favored new drugs for research in the world. However, some antibody drugs (such...
A Phase I Clinical Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of GB221 Injection and Trastuzumab (Herceptin®) in Healthy Chinese Adults [0.03%]
一项评价GB221注射液和曲妥珠单抗（赫赛汀）在中国健康受试者中的药代动力学、安全性和免疫原性的I期临床研究
Yu Zhu,Chen Li,Liming Chen et al.
Yu Zhu et al.
Background and objective: GB221 is a recombinant humanized anti-HER2 monoclonal antibody. The purpose of this study was to evaluate the pharmacokinetic, safety, and immunogenicity of GB221 in healthy Chinese adults in com...
Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals [0.03%]
评估阿布昔替尼对健康人群细胞色素P450 1A2、2B6和2C19酶探针底物及激素类口服避孕药药代动力学影响的研究
Xiaoxing Wang,Martin E Dowty,Sakambari Tripathy et al.
Xiaoxing Wang et al.
Background and objective: Abrocitinib is an oral small-molecule Janus kinase (JAK)-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis. In vitro studies indicated that abrocitinib is a weak time...
A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy Subjects [0.03%]
一项在健康受试者中进行的[14C]伊贝多米德药代动力学行为一期、开放标签试验
Yiming Cheng,Xiaomin Wang,Liangang Liu et al.
Yiming Cheng et al.
Background: Iberdomide is a novel potent cereblon modulator (CELMoD®) agent, which is currently under clinical development for hematological malignancies. A human mass balance study was conducted to characterize the biot...
Correction: Population Pharmacokinetic Analysis of Vancomycin in Patients with Solid or Hematological Malignancy in Relation to the Quick Sequential Organ Failure Assessment Scores [0.03%]
校正：实体或血液恶性肿瘤患者群体的万古霉素药代动力学分析与快速序贯器官衰竭评估分数的关系
Yasumasa Tsuda,Masahiro Takahashi,Fumiya Watanabe et al.
Yasumasa Tsuda et al.
Kinetic Characterization of Estradiol Glucuronidation by Liver Microsomes and Expressed UGT Enzymes: The Effects of Organic Solvents [0.03%]
雌二醇葡萄糖醛酸化反应的酶动力学特征：有机溶剂的影响
Caimei Wu,Meixue Luo,Dihao Xie et al.
Caimei Wu et al.
Background and objective: In vitro glucuronidation of 17β-estradiol (estradiol) is often performed to assess the role of uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1) in xenobiotic/drug metabolism. The object...
Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Clinical Pharmacokinetics [0.03%]
抗降钙素基因相关肽单克隆抗体在偏头痛中的应用：侧重于临床药代动力学
Slobodan M Janković,Snežana V Janković
Slobodan M Janković
The calcitonin gene-related peptide transmission was the target for recent development of drugs that effectively prevent attacks of both episodic and chronic migraine. The aim of this narrative review was to offer deeper insight into pharma...
Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions [0.03%]
抗降钙素基因相关肽单克隆抗体在偏头痛中的应用：关注药物相互作用
Slobodan M Janković,Snežana V Janković
Slobodan M Janković
Calcitonin gene-related peptide neurotransmission was the target for recent development of monoclonal antibodies that effectively prevent attacks of both episodic and chronic migraine. The aim of this narrative review was to offer deeper in...
Predicting Pharmacokinetics of Drugs Using Artificial Intelligence Tools: A Systematic Review [0.03%]
利用人工智能工具预测药物的药代动力学：系统性综述
Mahnaz Ahmadi,Bahareh Alizadeh,Seyed Mohammad Ayyoubzadeh et al.
Mahnaz Ahmadi et al.
Background and objective: Pharmacokinetic studies encompass the examination of the absorption, distribution, metabolism, and excretion of bioactive compounds. The pharmacokinetics of drugs exert a substantial influence on...
Safety, Tolerability, and Pharmacokinetics of the Monoamine Oxidase B Inhibitor, HEC122505, and its Major Metabolite After Single- and Multiple- Ascending Dose, and Food Effect Study in Healthy Chinese Subjects [0.03%]
单次和多次递增剂量以及食物影响研究中单胺氧化酶B抑制剂HEC122505及其主要代谢物在健康中国受试者中的安全性，耐受性和药代动力学研究
Chuanfei Jin,Chao Yi,Kangzhi Chen et al.
Chuanfei Jin et al.
Background and objectives: HEC122505 is a potent and selectively monoamine oxidase B inhibitor that is safe and well-tolerated in preclinical models of Parkinson's disease. The objectives of single ascending dose and mult...